Table 2.
Clinical characteristics by type of microorganisma
| None (n = 51) | Enterobacteriaceae including E. coli (n = 35) | Klebsiella (n = 21) | S. milleri (n = 19) | Other Strep spp. (n = 7) | Anaerobe (n = 16) | Other (n = 13) | Amoebic (n = 9) | p-valueb | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Abscess | ||||||||||
| Number of abscesses | 1 | 27 (52.9%) | 19 (54.3%) | 13 (61.9%) | 12 (63.2%) | 5 (71.4%) | 8 (50.0%) | 6 (46.2%) | 7 (77.8%) | p = 0.80 |
| 2+ | 24 (47.1%) | 16 (45.7%) | 8 (38.1%) | 7 (36.8%) | 2 (28.6%) | 8 (50.0%) | 7 (53.9%) | 2 (22.2%) | ||
| Max diameter | (cm) | 5.4 (3.9, 7.5) | 6.0 (4.3, 8.0) | 8.0 (5.3, 9.0) | 8.5 (5.7, 12.0) | 8.0 (6.8, 10.0) | 6.0 (3.3, 7.5) | 7.3 (5.6, 8.3) | 7.3 (5.8, 8.8) | p = 0.04 |
| Loculated | Yes | 15 (29.4%) | 15 (42.9%) | 11 (52.4%) | 10 (52.6%) | 4 (57.1%) | 3 (18.8%) | 7 (53.9%) | 1 (11.1%) | p = 0.09 |
| Resistancec | Yes | – | 26 (74.3%) | 15 (71.4%) | 3 (15.8%) | 1 (14.3%) | 2 (12.5%) | 7 (53.9%) | – | p < 0.001 |
| Other pathologyd | ||||||||||
| None | 32 (62.8%) | 20 (57.1%) | 17 (81.0%) | 13 (68.4%) | 5 (71.4%) | 10 (62.5%) | 7 (53.9%) | 9 (100.0%) | p = 0.52 | |
| Biliary malignancy | 4 (7.8%) | 2 (5.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (6.3%) | 0 (0.0%) | 0 (0.0%) | ||
| Non-malignant biliary | 4 (7.8%) | 6 (17.1%) | 1 (4.8%) | 2 (10.5%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
| Non-malignant GI | 10 (19.6%) | 6 (17.1%) | 2 (9.5%) | 4 (21.1%) | 2 (28.6%) | 4 (25.0%) | 6 (46.2%) | 0 (0.0%) | ||
| Other cancer | 1 (2.0%) | 1 (2.9%) | 1 (4.8%) | 0 (0.0%) | 0 (0.0%) | 1 (6.3%) | 0 (0.0%) | 0 (0.0%) | ||
| Biochemistry on admission | ||||||||||
| WBC (× 109/L) | 14.8 (10.8, 17.1) | 16.6 (12.2, 21.7) | 14.8 (12.9, 16.9) | 16.0 (12.9, 20.0) | 16.4 (10.6, 21.3) | 14.6 (10.6, 20.3) | 14.5 (10.5, 19.3) | 16.5 (13.9, 19.2) | p = 0.61 | |
| Neutrophils (×109/L) | 11.9 (8.0, 13.9) | 14.5 (8.9, 19.3) | 13.0 (9.9, 14.3) | 13.8 (11.3, 19.3) | 13.1 (8.4, 13.5) | 12.9 (8.5, 18.8) | 12.3 (8.9, 17.5) | 12.9 (9.3, 14.6) | p = 0.52 | |
| Hb (g/L) | 117 (102, 134) | 109 (96, 128) | 110 (106, 121) | 113 (101, 131) | 105 (100, 120) | 107 (100, 129) | 105 (99, 141) | 128 (118, 130) | p = 0.62 | |
| CRP (mg/L) | 215 (106, 279) | 204 (69, 286) | 228 (150, 276) | 223 (119, 286) | 245 (138, 333) | 188 (90, 258) | 173 (78, 263) | 260 (207, 408) | p = 0.40 | |
| INR | 1.20 (1.04, 1.44) | 1.30 (1.10, 1.40) | 1.20 (1.17, 1.45) | 1.22 (1.10, 1.48) | 1.30 (1.12, 1.40) | 1.12 (1.00, 1.40) | 1.12 (1.10, 1.45) | 1.17 (1.07, 1.30) | p = 0.59 | |
| ALT (IU/L) | 44 (20, 104) | 35 (15, 69) | 78 (48, 143) | 30 (24, 46) | 47 (20, 132) | 43 (22, 115) | 76 (48, 141) | 40 (25, 65) | p = 0.003 | |
| ALP (IU/L) | 146 (91, 252) | 170 (98, 268) | 186 (118, 297) | 168 (111, 250) | 237 (62, 319) | 158 (105, 228) | 297 (105, 319) | 156 (125, 225) | p = 0.79 | |
| BILI (umol/L) | 15 (10, 24) | 20 (11, 35) | 20 (11, 45) | 16 (9, 29) | 9 (9, 61) | 14 (11, 44) | 34 (10, 77) | 16 (11, 17) | p = 0.66 | |
aOf the 141 patients, 51 patients had no microorganism isolated, 81 had 1 or more bacterial spp. (120 in total) and 9 patients had amoebic liver abscesses
bFor continuous measures, F statistic comparing Somer’s D parameters for association of measure with organism type, adjusted for clustering within patients; for categorical variables, Fisher’s exact test
cResistance detected to one or more antimicrobial agents; overall, resistance was detected in 54/111 (48.7%) of isolated microorganisms
dBiliary Malignancies (cholangiocarcinoma); other biliary pathology (gallstones, cholangitis/cholecystitis); Non-malignant GI pathology (diverticulitis, fistula, portal vein thrombosis); Other cancer (metastatic melanoma, colorectal cancer, pancreatic cancer)